Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement
Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement
Authors: Ludger Klimek Marek Jutel Cezmi Akdis Jean Bousquet Mübeccel Akdis Claus Bachert Ioana Agache Ignacio Ansotegui Anna Bedbrook Sinthia Bosnic‐Anticevich Giorgio W Canonica Tomas Chivato Alvaro A Cruz Wiencyslawa Czarlewski Stefano Del Giacco Hui Du Joao A Fonseca Yadong Gao Tari Haahtela Karin Hoffmann‐Sommergruber Juan‐Carlos Ivancevich Nikolai Khaltaev Edward F Knol Piotr Kuna Desiree Larenas‐Linnemann Erik Melen Joaquim Mullol Robert Naclerio Ken Ohta Yoshitaka Okamoto Liam O’Mahony Gabrielle L Onorato Nikos G Papadopoulos Ruby Pawankar Oliver Pfaar Boleslaw Samolinski Jurgen Schwarze Sanna Toppila‐Salmi Mohamed H. Shamji Maria Teresa Ventura Arunas Valiulis Arzu Yorgancioglu Paolo Matricardi Torsten Zuberbier The ARIA‐MASK study group
Abstract
The current COVID‐19 pandemic influences many areas of social life, medical treatments and the way allergy is performed. Allergen‐specific immunotherapy (AIT) is one of the most important treatment options for IgE‐mediated allergies and is based on immunological effects on the diseased patient
Doi: 10.1111/all.14336
Comentarios
Publicar un comentario